Pharmaceuticals company Amrutanjan Health Care announced Q1FY27 results Financial Highlights: Revenue from Operations: For Q1FY27, revenue stood at Rs 10,296.88 lakh, marking a YoY growth of 9.49% compared to Rs 9,404.57 lakh in Q1FY26, while recording a QoQ decrease of 31.25% from Rs 14,976.81 lakh in Q4FY26. Total Income: Total income for the quarter was Rs 10,678.36 lakh, an increase of 8.44% YoY from Rs 9,847.31 lakh in Q1FY26 and a decline of 30.88% QoQ from Rs 15,449.87 lakh in Q4FY26. Profit Before Tax (PBT): PBT reached Rs 606.94 lakh in Q1FY27, representing a YoY decrease of 46.25% from Rs 1,129.27 lakh in Q1FY26 and a QoQ decrease of 71.12% from Rs 2,101.62 lakh in Q4FY26. Net Profit: Profit after tax for Q1FY27 was reported at Rs 436.57 lakh, down 47.47% YoY from Rs 831.12 lakh in Q1FY26 and down 73.04% QoQ from Rs 1,619.28 lakh in Q4FY26. Total Comprehensive Income: The company recorded a total comprehensive income of Rs 401.78 lakh for Q1FY27, showing a YoY decline of 51.33% from Rs 825.49 lakh in Q1FY26 and a QoQ decline of 75.36% from Rs 1,630.47 lakh in Q4FY26. Earnings Per Share (EPS): Basic and Diluted EPS (not annualised) for Q1FY27 stood at Rs 1.51, compared to Rs 2.87 in Q1FY26 and Rs 5.60 in Q4FY26. Business Highlights: Segment Wise Performance: OTC Products: This segment recorded revenue of Rs 5,725.83 lakh in Q1FY27 (compared to Rs 5,697.24 lakh in Q1FY26) and a segment result of Rs 987.44 lakh. Women's Hygiene & Personal Care: The segment reached revenue of Rs 3,635.77 lakh in Q1FY27 (compared to Rs 2,860.75 lakh in Q1FY26) and reported a segment loss of Rs 287.61 lakh. Beverages: Revenue for the quarter was Rs 863.59 lakh (compared to Rs 778.01 lakh in Q1FY26), with a segment loss of Rs 125.98 lakh. Others (Pain Management Centre): Revenue stood at Rs 71.69 lakh for Q1FY27, with a segment result of Rs 3.39 lakh. Exceptional Item: The company recognized an exceptional item of Rs 202.75 lakh during Q1FY27. This represents an additional cost settled by the management following a revised lease rent demand from the HR & CE Department for leasehold land. Dividend: The company has fixed Friday, September 11, 2026, as the record date for determining shareholder eligibility for the payment of the Final Dividend. ESOP Schemes: The 'ESOP 2 Scheme' was withdrawn due to the non-satisfaction of turnover conditions. Subsequently, the Board approved further grants under the 'Second Phase ESOP 2 Scheme' on May 7, 2025. Product Renaming: Pursuant to the launch of new products, the "Women's Hygiene" segment has been renamed "Women's Hygiene & Personal Care." Result PDF